- Home
- WLGS vs CERO Comparison
WLGS vs CERO Comparison
Compare WLGS & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- CERO
- Stock Information
- Founded
- WLGS 1981
- CERO 2017
- Country
- WLGS Hong Kong
- CERO United States
- Employees
- WLGS N/A
- CERO N/A
- Industry
- WLGS Engineering & Construction
- CERO
- Sector
- WLGS Consumer Discretionary
- CERO
- Exchange
- WLGS Nasdaq
- CERO Nasdaq
- Market Cap
- WLGS 3.0M
- CERO 3.5M
- IPO Year
- WLGS 2023
- CERO N/A
- Fundamental
- Price
- WLGS $0.05
- CERO $7.97
- Analyst Decision
- WLGS
- CERO Strong Buy
- Analyst Count
- WLGS 0
- CERO 2
- Target Price
- WLGS N/A
- CERO $45.00
- AVG Volume (30 Days)
- WLGS 144.7M
- CERO 62.9K
- Earning Date
- WLGS 08-19-2025
- CERO 08-22-2025
- Dividend Yield
- WLGS N/A
- CERO N/A
- EPS Growth
- WLGS N/A
- CERO N/A
- EPS
- WLGS N/A
- CERO N/A
- Revenue
- WLGS $3,951,649.00
- CERO N/A
- Revenue This Year
- WLGS N/A
- CERO N/A
- Revenue Next Year
- WLGS N/A
- CERO N/A
- P/E Ratio
- WLGS N/A
- CERO N/A
- Revenue Growth
- WLGS N/A
- CERO N/A
- 52 Week Low
- WLGS $0.03
- CERO $6.71
- 52 Week High
- WLGS $9.66
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- WLGS 45.71
- CERO 46.67
- Support Level
- WLGS $0.04
- CERO $7.80
- Resistance Level
- WLGS $0.08
- CERO $8.09
- Average True Range (ATR)
- WLGS 0.01
- CERO 0.50
- MACD
- WLGS 0.00
- CERO 0.13
- Stochastic Oscillator
- WLGS 17.37
- CERO 76.32
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED. WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, water supply and sewage disposal systems, and site project management.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.